Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the ...

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

Telesis intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) to remove its Common Stock from listing on the Nasdaq Global Select Market on or about September 20, 2024. As ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 74.84% ...

Custom MIPSA antigen libraries can also be created to address specific research needs. About Infinity Bio Infinity Bio, Inc.

Instil Bio Inc (TIL) stock saw a modest uptick, ending the day at $21.99 which represents a slight increase of $7.74 or 54.32% from the prior close of $14.25. The stock opened at $16.4 and touched a ...

Instil Bio, Inc. (NASDAQ:TIL) recently traded higher on the back of analyst raising their price target on shares because of how much the PD-1/VEGF bispecific antibody space is heating up.

Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based ...

The considerable ownership by retail investors in Annovis Bio indicates that they collectively ... want to know who really controls Annovis Bio, Inc. (NYSE:ANVS), then you'll have to look at ...

Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, ...

Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, ...

SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...